{"id":76486,"date":"2026-08-25T12:06:26","date_gmt":"2026-08-25T04:06:26","guid":{"rendered":"https:\/\/flcube.com\/?p=76486"},"modified":"2026-08-25T12:06:27","modified_gmt":"2026-08-25T04:06:27","slug":"innocare-pharma-swings-to-profit-as-h1-2026-revenue-jumps-55-5-on-orelabrutinib-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76486","title":{"rendered":"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>InnoCare Pharma Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/9969:HKG\">HKG: 9969<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688428:SHA\">SHA: 688428<\/a>) reported <strong>interim results for the first half of 2026<\/strong> on Aug. 25, posting total revenue of <strong>RMB 1.14 billion<\/strong>, up <strong>55.5% year\u2011on\u2011year<\/strong>, and a <strong>net profit of RMB 240 million<\/strong> \u2014 turning losses into profits compared with the same period last year.<\/p>\n\n\n\n<h2 id=\"h-h1-2026-financial-highlights\" class=\"wp-block-heading\">H1 2026 Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>2026 H1<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>RMB 1.14 billion<\/td><td><strong>+55.5%<\/strong><\/td><\/tr><tr><td><strong>Drug Revenue<\/strong><\/td><td>RMB 920 million<\/td><td><strong>+43.2%<\/strong><\/td><\/tr><tr><td><strong>Net Profit<\/strong><\/td><td>RMB 240 million<\/td><td><strong>Turned profitable YoY<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-revenue-drivers\" class=\"wp-block-heading\">Revenue Drivers<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Orelabrutinib (BTK inhibitor):<\/strong> The flagship product remained the primary growth engine, sustaining rapid commercial expansion.<\/li>\n\n\n\n<li><strong>Tafasitamab (CD19 monoclonal antibody):<\/strong> Approved in 2025, contributing incremental revenue during the reporting period.<\/li>\n\n\n\n<li><strong>Zurletrectinib (TRK inhibitor):<\/strong> The second 2025\u2011approved innovative drug also added to drug sales, broadening InnoCare&#8217;s commercialized portfolio.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-amp-pipeline-milestones\" class=\"wp-block-heading\">Regulatory &amp; Pipeline Milestones<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Orelabrutinib \u2013 Australia:<\/strong> Received <strong>marketing approval in Australia<\/strong> during the reporting period, extending the drug&#8217;s international footprint.<\/li>\n\n\n\n<li><strong>Orelabrutinib \u2013 ITP (China):<\/strong> The <strong>New Drug Application (NDA)<\/strong> for the treatment of <strong>primary immune thrombocytopenia (ITP)<\/strong> was <strong>accepted by China&#8217;s National Medical Products Administration (NMPA)<\/strong> \u2014 a key milestone marking the drug&#8217;s expansion <strong>from hematological oncology into autoimmune diseases<\/strong>, with potential to address the treatment needs of more patients.<\/li>\n\n\n\n<li><strong>Zurletrectinib \u2013 Pediatric Solid Tumors (China):<\/strong> The <strong>NDA in pediatric solid tumors<\/strong> was also <strong>accepted by the NMPA<\/strong>, potentially widening the TRK inhibitor&#8217;s indication coverage.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Path to Sustainable Profitability:<\/strong> The swing to a <strong>RMB 240 million net profit<\/strong> underscores InnoCare&#8217;s transition from a development\u2011stage biotech to a commercial\u2011phase company, underpinned by double\u2011digit revenue growth.<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> With three marketed innovative drugs and orelabrutinib&#8217;s push into autoimmune indications, InnoCare is building a broader commercial base beyond its oncology core.<\/li>\n\n\n\n<li><strong>Label Expansion:<\/strong> Acceptance of the ITP and pediatric solid tumor NDAs sets the stage for additional launches in China, reinforcing the company&#8217;s long\u2011term growth trajectory.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding InnoCare Pharma&#8217;s financial performance, regulatory approvals and commercialization prospects. Actual results may differ due to risks including clinical outcomes, regulatory decisions, market adoption and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082400764.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082400764.\"><\/object><a id=\"wp-block-file--media-68917b38-2c6d-4326-a6e9-0ec1085e3760\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082400764.pdf\">2026082400764<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082400764.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-68917b38-2c6d-4326-a6e9-0ec1085e3760\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76490,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,919,327,920],"class_list":["post-76486","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-9969","tag-innocare-pharma","tag-sha-688428"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of 2026 on Aug. 25, posting total revenue of RMB 1.14 billion, up 55.5% year\u2011on\u2011year, and a net profit of RMB 240 million \u2014 turning losses into profits compared with the same period last year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76486\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth\" \/>\n<meta property=\"og:description\" content=\"InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of 2026 on Aug. 25, posting total revenue of RMB 1.14 billion, up 55.5% year\u2011on\u2011year, and a net profit of RMB 240 million \u2014 turning losses into profits compared with the same period last year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76486\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-25T04:06:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-25T04:06:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76486#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76486\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth\",\"datePublished\":\"2026-08-25T04:06:26+00:00\",\"dateModified\":\"2026-08-25T04:06:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76486\"},\"wordCount\":349,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76486#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2501.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 9969\",\"InnoCare Pharma\",\"SHA: 688428\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76486#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76486\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76486\",\"name\":\"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76486#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76486#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2501.webp\",\"datePublished\":\"2026-08-25T04:06:26+00:00\",\"dateModified\":\"2026-08-25T04:06:27+00:00\",\"description\":\"InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of 2026 on Aug. 25, posting total revenue of RMB 1.14 billion, up 55.5% year\u2011on\u2011year, and a net profit of RMB 240 million \u2014 turning losses into profits compared with the same period last year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76486#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76486\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76486#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2501.webp\",\"width\":1080,\"height\":608,\"caption\":\"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76486#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth - Insight, China&#039;s Pharmaceutical Industry","description":"InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of 2026 on Aug. 25, posting total revenue of RMB 1.14 billion, up 55.5% year\u2011on\u2011year, and a net profit of RMB 240 million \u2014 turning losses into profits compared with the same period last year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76486","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth","og_description":"InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of 2026 on Aug. 25, posting total revenue of RMB 1.14 billion, up 55.5% year\u2011on\u2011year, and a net profit of RMB 240 million \u2014 turning losses into profits compared with the same period last year.","og_url":"https:\/\/flcube.com\/?p=76486","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-25T04:06:26+00:00","article_modified_time":"2026-08-25T04:06:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76486#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76486"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth","datePublished":"2026-08-25T04:06:26+00:00","dateModified":"2026-08-25T04:06:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76486"},"wordCount":349,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76486#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2501.webp","keywords":["Finanical Reports","HKG: 9969","InnoCare Pharma","SHA: 688428"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76486#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76486","url":"https:\/\/flcube.com\/?p=76486","name":"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76486#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76486#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2501.webp","datePublished":"2026-08-25T04:06:26+00:00","dateModified":"2026-08-25T04:06:27+00:00","description":"InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of 2026 on Aug. 25, posting total revenue of RMB 1.14 billion, up 55.5% year\u2011on\u2011year, and a net profit of RMB 240 million \u2014 turning losses into profits compared with the same period last year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76486#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76486"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76486#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2501.webp","width":1080,"height":608,"caption":"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76486#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2501.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76486"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76486\/revisions"}],"predecessor-version":[{"id":76491,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76486\/revisions\/76491"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76490"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}